The spectrum of mycobacterial infection after lung transplantation

被引:117
作者
Malouf, MA [1 ]
Glanville, AR [1 ]
机构
[1] St Vincents Hosp, Heart Lung Transplant Unit, Darlinghurst, NSW 2010, Australia
关键词
D O I
10.1164/ajrccm.160.5.9808113
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Despite the success of lung transplantation, infection is one of the leading causes of morbidity and mortality. Mycobacterial infections have been reported rarely, with the majority due to Mycobacterium tuberculosis. Our aim was to assess the incidence, etiology, and clinical outcome of mycobacterial infection after lung transplantation; to do so, we have studied retrospectively all lung and heart-lung transplants performed over a 12-yr period between November 1986 and lune 1998 (n = 261). Twenty-three patients (9%) (M:F, 11:12) were diagnosed with mycobacterial infections in 25 sites, including n = 19, pulmonary (M. avium complex [n = 13], M. tuberculosis [n = 2], M. abscessus [n = 2], M. asiaticum [n = 1], and M. kansasii [n = 1]) and n = 6 extrapulmonary (M. haemophilum [n = 5] and M. obscessus [n = 1]) infections. Time to diagnosis from transplantation was 677 +/- 735 d (range, 2-3,086 d). Three episodes of transient colonization with M. avium were not treated; the remaining (22 of 25, 88%) were treated. Initial baseline therapy for nontuberculous mycobacteria included clarithromycin, rifampicin, ciprofloxacin, and/or ethambutol. All cutaneous lesions resolved completely, while clinical and graft function improved in 11 of 16 (69%) and 8 of 16 (50%) of patients treated, respectively. Seventeen of 23 patients (72%) survived at a follow-up of 1,658 +/- 759 d (range, 522-3,285 d). Complications, predominantly due to rifampicin, included gastrointestinal intolerance and an increased tendency for rejection. There were no deaths attributable to mycobacterial disease or therapy. We conclude that mycobacterial infection, particularly due to nontuberculous mycobacteria, is relatively common after lung transplantation and may be an unrecognized cause of graft dysfunction. Early treatment of cutaneous lesions is associated with excellent control; however, graft dysfunction may be permanent. Although drug toxicity and interactions with immunosuppressive agents were not infrequent, the majority of these infections can be managed successfully.
引用
收藏
页码:1611 / 1616
页数:6
相关论文
共 19 条
[1]  
AHN CH, 1982, AM REV RESPIR DIS, V105, P683
[2]   TREATMENT OF TUBERCULOSIS AND TUBERCULOSIS INFECTION IN ADULTS AND CHILDREN [J].
BASS, JB ;
FARER, LS ;
HOPEWELL, PC ;
OBRIEN, R ;
JACOBS, RF ;
RUBEN, F ;
SNIDER, DE ;
THORNTON, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (05) :1359-1374
[3]   RIFABUTIN - A REVIEW OF ITS ANTIMICROBIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
BROGDEN, RN ;
FITTON, A .
DRUGS, 1994, 47 (06) :983-1009
[4]   INFECTIOUS COMPLICATIONS IN HEART-LUNG TRANSPLANT RECIPIENTS [J].
BROOKS, RG ;
HOFFLIN, JM ;
JAMIESON, SW ;
STINSON, EB ;
REMINGTON, JS .
AMERICAN JOURNAL OF MEDICINE, 1985, 79 (04) :412-422
[5]  
BUFFINGTON GA, 1958, JAMA-J AM MED ASSOC, V236, P1958
[6]  
DROMER C, 1993, J HEART LUNG TRANSPL, V12, P924
[7]   INFECTIONS IN HEART-LUNG TRANSPLANT RECIPIENTS [J].
DUMMER, JS ;
MONTERO, CG ;
GRIFFITH, BP ;
HARDESTY, RL ;
PARADIS, IL ;
HO, M .
TRANSPLANTATION, 1986, 41 (06) :725-729
[8]   INVITRO AND INVIVO ACTIVITIES OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM [J].
FERNANDES, PB ;
HARDY, DJ ;
MCDANIEL, D ;
HANSON, CW ;
SWANSON, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1531-1534
[9]  
GOUBY AB, 1988, J MED MICROBIOL, V25, P46
[10]   ADVERSE EVENTS ASSOCIATED WITH HIGH-DOSE RIFABUTIN IN MACROLIDE-CONTAINING REGIMENS FOR THE TREATMENT OF MYCOBACTERIUM-AVIUM COMPLEX LUNG-DISEASE [J].
GRIFFITH, DE ;
BROWN, BA ;
GIRARD, WM ;
WALLACE, RJ .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (03) :594-598